Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

References

• Defrancesco I, Zerbi C, Rattotti S, et al. HCV infection and non-Hodgkin lymphomas: an evolving story. Clin Exp Med. 2020. doi: 10.1007/s10238-020-00615-6
   PubMed Web of Science ®Google Scholar
• Rattotti S, on behalf of the “Rete Ematologica Lombarda” (REL ‐ Hematology Clinical Network of Lombardy ‐ Lymphoma Workgroup), Ferretti VV, Rusconi C, et al. Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. Hematol Oncol. 2019;37(2):160–167.
   PubMed Web of Science ®Google Scholar
• Michot J, on behalf of the ANRS HC-13 Lympho-C Study Group, Canioni D, Driss H, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas. Am J Hematol. 2015;90(3):197–203.
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003;102(3):996–999.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Santambrogio E, Castellino A, et al. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. Expert Rev Hematol. 2017;10(8):697–705.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. JCO. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132(8):777–781.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JCO. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Klausen U, Jørgensen NGD, Grauslund JH, et al. Cancer immune therapy for lymphoid malignancies: recent advances. Semin Immunopathol. 2019;41(1):111–124.
   PubMed Web of Science ®Google Scholar
• Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B-cell non-Hodgkin’s lymphoma. Hepatology. 2018;67(1):48–55.
   PubMed Web of Science ®Google Scholar
• Merli M, Frigeni M, Alric L, et al. Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas. Oncologist. 2019;24(8):e720–e729.
   PubMed Web of Science ®Google Scholar
• Merli M, Rattotti S, Gotti M, et al. Antiviral therapies for managing viral hepatitis in lymphoma patients. Expert Opin Pharmacother. 2017;18(4):363–376.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523–541.
   PubMed Web of Science ®Google Scholar
• Merli M, Frigeni M, Gotti M, et al. Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large B-cell lymphomas. Hepatology. 2017;66(4):1341–1343.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant. 2016;22(4):717–722.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The updated who classification of hematological malignancies The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2391.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32(27):3059–3067.
   PubMed Web of Science ®Google Scholar
• EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153–194.
   PubMed Web of Science ®Google Scholar
• Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489–496.
   PubMed Web of Science ®Google Scholar
• Occhipinti V, Farina L, Viganò M, et al. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. Dig Liver Dis. 2019;51(5):719–723.
   PubMedGoogle Scholar
• Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85(1):46–50.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116(24):5119–5125.
   PubMed Web of Science ®Google Scholar
• Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67(5):411–431.
   PubMed Web of Science ®Google Scholar
• Economides MP, Mahale P, Kyvernitakis A, et al. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016;44(11-12):1235–1241.
   PubMed Web of Science ®Google Scholar
• Torres HA, Economides MP, Angelidakis G, et al. Sofosbuvir-based therapy in hepatitis C virus-infected cancer patients: a prospective observational study. Am J Gastroenterol. 2019;114(2):250–257.
   Web of Science ®Google Scholar
• Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527–2532.
   PubMed Web of Science ®Google Scholar
• Frigeni M, Besson C, Visco C, et al. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2019. doi: 10.1038/s41375-019-0687-2
   PubMed Web of Science ®Google Scholar
• Arcaini L, Merli M, Volpetti S, et al. Indolent B-Cell lymphomas associated with HCV infection: Clinical and virological features and role of antiviral therapy. Clin Dev Immunol. 2012;2012:1–10.
   Google Scholar